SOL J BARER
CIK 1247015 · Executive Chairman · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$49.41M
Companies
17
Total Filings
157
Lifetime Open-Market Net
-$126.37M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TEVA | Director | 448,011 | $34.63 | $15.51M | $2.00M | 22 | 2026-06-08 |
| NEXI | Director | 3,755,827 | $0.00 | $376 | $1.73M | 13 | 2023-07-07 |
| CONTRAFECT Corp (CFRX) Delisted | Director | 815,933 | $0.05 | $40.8K | $49.6K | 8 | 2022-05-18 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Director | — | $2.93 | — | $0 | 3 | 2021-06-17 |
| Aevi Genomic Medicine, LLC (GNMX) Delisted | Director | 1,181,878 | — | — | $2.74M | 8 | 2019-12-09 |
| PDSB | Director | 678,075 | $1.05 | $712.0K | $0 | 1 | 2019-03-18 |
| EDGE | Director | 658,075 | $49.07 | $32.29M | $495.0K | 6 | 2018-08-15 |
| InspireMD, Inc. (NSPR.WS) Delisted | Director | — | $0.05 | — | $0 | 1 | 2016-12-08 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Director | 0 | — | — | $0 | 6 | 2016-11-30 |
| NSPR | Director | 1,226,690 | $0.73 | $895.5K | $2.31M | 22 | 2016-07-11 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 45,000 | $14.49 | $652.0K | $167.6K | 10 | 2016-06-13 |
| CONTRAFECT Corp (CFRX.W) Delisted | Director | — | — | — | $0 | 1 | 2016-05-10 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Director | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Director | 560,846 | — | — | $4.69M | 15 | 2015-10-08 |
| CONTRAFECT Corp (CFRX.Z) Delisted | Director | — | — | — | $0 | 2 | 2015-05-06 |
| CELGENE CORP /DE/ (CELGZ) Delisted | Director | 828,673 | — | — | -$4.32M | 2 | 2011-01-14 |
| CELGENE CORP /DE/ (CELG) Delisted | Executive Chairman | 810,541 | — | — | -$136.24M | 26 | 2010-10-14 |
Recent Filings · Page 2 of 16
157 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-11-17 | NEXI | Buy (P) | +200,000 | $96.2K | EDGAR |
| 2022-08-08 | TEVA | Grant (A) | — | $0 | EDGAR |
| 2022-06-16 | TEVA | Exer (M) | +25,791 | $0 | EDGAR |
| 2022-06-15 | NEXI | Grant (A) | — | $0 | EDGAR |
| 2022-06-02 | NEXI | Buy (P) | +100,000 | $226.2K | EDGAR |
| 2022-05-18 | CONTRAFECT Corp (CFRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-24 | NEXI | Buy (P) | +10,000 | $26.7K | EDGAR |
| 2022-03-23 | NEXI | Buy (P) | +30,000 | $72.3K | EDGAR |
| 2022-03-22 | NEXI | Buy (P) | +30,000 | $64.1K | EDGAR |
| 2022-03-21 | NEXI | Buy (P) | +30,000 | $63.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.